ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p1.xmlBeaten at the Alamo by the Europeans2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p1.pdf2026-04-18Beaten at the Alamo by the Europeanshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-pxxvi.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-pxxvi.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-pxxiv.xmlErratum2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-pxxiv.pdf2026-04-18Erratumhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p13.xmlPersonalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p13.pdf2026-04-18Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p7.xmlLessons From ASH 2010: A Focus on NHL2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p7.pdf2026-04-18Lessons From ASH 2010: A Focus on NHLhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p4.xmlOvarian Cancer Guidelines: Treatment Progress and Controversies2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p4.pdf2026-04-18Ovarian Cancer Guidelines: Treatment Progress and Controversieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p82.xmlEpithelial Ovarian Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p82.pdf2026-04-18Epithelial Ovarian Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p121.xmlCounterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p121.pdf2026-04-18Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p65.xmlThe Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p65.pdf2026-04-18The Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromeshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p57.xmlEpidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 20102026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p57.pdf2026-04-18Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p115.xmlPoint: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p115.pdf2026-04-18Point: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p30.xmlMyelodysplastic Syndromes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p30.pdf2026-04-18Myelodysplastic Syndromeshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p126.xmlIndications for Minimally Invasive Surgery for Ovarian Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/1/article-p126.pdf2026-04-18Indications for Minimally Invasive Surgery for Ovarian Cancer